Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
暂无分享,去创建一个
O. Anzala | V. Bockstal | M. Douoguih | D. Anumendem | K. Luhn | G. Mutua | C. Robinson
[1] S. Kapiga,et al. Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania , 2019, The Journal of infectious diseases.
[2] H. Schuitemaker,et al. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates , 2018, PloS one.
[3] D. Wolfe,et al. Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs. , 2017, Vaccine.
[4] Pierre-Stéphane Gsell,et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report , 2017, The Lancet. Infectious diseases.
[5] A. Gulland. WHO ready to deploy Ebola vaccine in disease outbreak , 2017, British Medical Journal.
[6] T. Lambe,et al. A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? , 2017, Philosophical Transactions of the Royal Society B: Biological Sciences.
[7] M. Voysey,et al. Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year , 2017, JAMA.
[8] John-Arne Røttingen,et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) , 2017, The Lancet.
[9] C. Truyers,et al. Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults , 2016 .
[10] H. Schuitemaker,et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. , 2016, JAMA.
[11] Andrew Rambaut,et al. Reduced evolutionary rate in reemerged Ebola virus transmission chains , 2016, Science Advances.
[12] James D. Campbell,et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial , 2016, The Lancet. Infectious diseases.
[13] J. Farrar,et al. The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats , 2015, The Lancet Infectious Diseases.
[14] Anne M Johnson,et al. Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control , 2015, BMC Medicine.
[15] Jeffrey R. Kugelman,et al. Possible Sexual Transmission of Ebola Virus — Liberia, 2015 , 2015, MMWR. Morbidity and mortality weekly report.
[16] Mosoka P. Fallah,et al. Harnessing Case Isolation and Ring Vaccination to Control Ebola , 2015, PLoS neglected tropical diseases.
[17] H. Schuitemaker,et al. Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species , 2012, PloS one.
[18] Allan C. deCamp,et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. , 2012, The Journal of clinical investigation.
[19] C. King,et al. Do Antenatal Parasite Infections Devalue Childhood Vaccination? , 2009, PLoS neglected tropical diseases.
[20] C. Petropoulos,et al. Natural Variation of Drug Susceptibility in Wild-Type Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.
[21] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[22] P. van der Stuyft,et al. Short communication: A cluster of Marburg virus disease involving an infant * , 2002, Tropical medicine & international health : TM & IH.
[23] N. Mirza,et al. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya. , 1995, East African medical journal.
[24] F. Mosteller,et al. Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature , 1994 .
[25] P. Wright,et al. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. , 1991, Reviews of infectious diseases.
[26] O. Tomori,et al. Evaluation of measles vaccination programme conducted in two separate health centres. , 1992, Vaccine.
[27] R. Eggo,et al. Emerging Blockininfectious Blockindiseases Blockin@bullet Blockin Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease , 2022 .